Maxcyte (MXCT) Operating Expenses (2020 - 2026)

Maxcyte (MXCT) has 7 years of Operating Expenses data on file, last reported at $14.3 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 32.66% year-over-year to $14.3 million in Q1 2026; TTM through Mar 2026 was $71.8 million, a 12.14% decrease from a year earlier, with the FY2025 full-year figure at $78.7 million, down 4.86% from the prior year.
• Operating Expenses for Q1 2026 stood at $14.3 million, down from $16.9 million in the prior quarter.
• Over the last five years, Operating Expenses for MXCT reached as high as $22.2 million in Q1 2024 and fell as low as $14.3 million in Q1 2026.
• Historically, Operating Expenses has averaged $19.2 million across 5 years, with a median of $20.3 million in 2024.
• Across the five-year window, Operating Expenses surged 60.38% in 2022 and sank 32.66% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $17.6 million in 2022, then advanced by 25.87% to $22.2 million in 2023, then fell by 12.96% to $19.3 million in 2024, then retreated by 12.41% to $16.9 million in 2025, then fell by 15.66% to $14.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $14.3 million in Q1 2026, $16.9 million in Q4 2025, and $19.4 million in Q3 2025.